Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 154.42 (-2.98), ZIOP: 9.17 (-0.17), PFE: 33.99 (+0.05), XON: 40.08 (-0.90), AMGN: 162.36 (+0.38), GSK: 44.77 (-0.22), IMUC: 0.48 (+0.01), CELG: 115.53 (+0.45), JNJ: 102.30 (+0.47), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 154.42 (-2.98), CLRB: 2.74 (+0.08), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)